Literature DB >> 30448334

A cross-sectional study of Bordetella pertussis seroprevalence and estimated duration of vaccine protection against pertussis in St. Petersburg, Russia.

Natalia Kurova1, Elena V Timofeeva2, Nicole Guiso3, Denis Macina4.   

Abstract

BACKGROUND: In Russia as in other countries introduction of infant vaccination against pertussis in 1950s led to dramatic decrease of whooping cough. The current vaccination schedule includes a 3-dose infant series and toddler booster; the pre-school booster was cancelled in 1980s and never reintroduced. Whole-cell vaccines, and in a smaller proportion acellular vaccines are used for all doses. However, pertussis incidence in urban settings is high with highest burden in school children. We conducted a study of seroprevalence of recent pertussis infection to estimate the duration of protection from the 4-dose series.
MATERIALS AND METHODS: Sera sample from 395 St Petersburg children aged ≥3 years and <14 years were tested for pertussis toxin antibodies using a commercial PT ELISA test. Only children with completed 4-dose vaccination course were included in the study. Age-specific seroprevalence of recent pertussis infection was analyzed for trends.
RESULTS: Children fully vaccinated against pertussis at 3 years old had significant delays in infant vaccination schedule: only 83.5% received at least one dose of pertussis vaccine at 6 months of age and 25.6% received their toddler booster before 24 months-old. Overall, 10.6% of children demonstrated the serological signs of the infection in the last 12 months. A clear trend (r2 = 0.692) of increasing proportion of infection in the last 12 months was observed in children who had received their last dose of vaccine 6 years and more prior to the study.
CONCLUSION: Our study demonstrates that Russian children become susceptible to infection at or soon after entering school. The results confirm the waning of vaccine-elicited immunity around school-age and support the need for a booster dose at that age.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Pertussis; Seroprevalence; Vaccines; Waning

Mesh:

Substances:

Year:  2018        PMID: 30448334     DOI: 10.1016/j.vaccine.2018.11.007

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Is it time to administer acellular pertussis vaccine to childbearing age/pregnant women in all areas using whole-cell pertussis vaccination schedule?

Authors:  Abdoulreza Esteghamati; Shirin Sayyahfar; Yousef Alimohamadi; Sarvenaz Salahi; Mahmood Faramarzi
Journal:  Ther Adv Vaccines Immunother       Date:  2021-05-25

2.  Post-Marketing Surveillance of Tetravalent Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus (DTaP-IPV) Vaccine in South Korea, 2009 to 2015.

Authors:  Young June Choe; Emmanuel Vidor; Christine Manson
Journal:  Infect Dis Ther       Date:  2022-05-14

3.  Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study.

Authors:  Victor Romanenko; Irina Osipova; Anna Galustyan; Michael Scherbakov; Nathalie Baudson; Déborah Farhi; Luis Anaya; Sherine O Kuriyakose; Nadia Meyer; Winnie Janssens
Journal:  Hum Vaccin Immunother       Date:  2020-02-12       Impact factor: 3.452

4.  Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study.

Authors:  Asmik Asatryan; Nadia Meyer; Michael Scherbakov; Victor Romanenko; Irina Osipova; Anna Galustyan; Olga Shamsheva; Tatiana Latysheva; Tatyana Myasnikova; Nathalie Baudson; Monique Dodet; Stebin Xavier; Lauriane Harrington; Anastasia Kuznetsova; Laura Campora; Peter Van den Steen
Journal:  Hum Vaccin Immunother       Date:  2020-08-26       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.